Chordoma: The Quest for Better Treatment Options. Issue 1 (June 2016)

• Record Type: Journal Article
• Authors: Heery, Christopher
• Is Part Of: Oncology and therapy. Volume 4:Issue 1(2016)
• Page Start: 35
• Page End: 51
• Publication Date: 2016-06
• Subjects: Brachyury -- Chordoma -- Erlotinib -- Imatinib -- Immunotherapy -- Radiotherapy -- Spine tumor -- Surgery -- Vaccine; Oncology -- Periodicals; Oncology; Neoplasms; Neoplasms -- therapy; Periodicals; Electronic journals; Periodicals; 616.99406
• DOI: 10.1007/s40487-016-0016-0
• Languages: English
• ISSNs: 2366-1070

Abstract

Abstract Chordoma is an extremely rare cancer, with an incidence of about one case per million persons per year in the USA and Europe (about 300 and 450 cases per year, respectively). The estimated median overall survival of patients with chordoma is approximately 6–7 years, yielding a rough estimate of chordoma prevalence at about 2000 in the USA and 3000 in Europe. Primary tumor develops along the axial spine between the clivus and sacrum and develops from the residual embryonic notochord. Brachyury (T), a transcription factor required for normal embryonic development, is expressed in the notochord and overexpressed in almost all cases of chordoma. The primary treatment for chordoma is surgical excision with wide local margins, when possible. Radiotherapy also plays a significant role in the adjuvant setting and when surgery is not possible. Unfortunately, in the advanced and/or metastatic setting, where the role of surgery and/or radiation is less clear, treatment options are very limited. To date, there have been no randomized, controlled trials in chordoma that have resulted in defined agents of clinical benefit for systemic treatment. This review briefly describes the natural history and initial treatment of chordoma and focuses on treatment options for advanced disease and potential avenues of research that may lead to improved treatment options in the future.